Corbus Pharma CBO buys 2,600 company shares

Corbus Pharmaceuticals Holdings, Inc. Chief Business Officer Nishant C Saxena purchased 2,600 shares of common stock on 2026-08-11 at an average price of $9.6294 per share in a direct open-market or private transaction.

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. Chief Business Officer Nishant C Saxena purchased 2,600 shares of common stock on 2026-08-11 at an average price of $9.6294 per share in a direct open-market or private transaction. Following this trade, his direct holdings total 77,900 shares, which the footnote states include 58,300 unvested RSUs subject to a vesting schedule. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 2,600 shares

Net Buy 1 txn

Insider Saxena Nishant C

Role Chief Business Officer

Bought 2,600 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share F1	2,600	$9.6294	$25K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 77,900 shares (Direct)

Footnotes (1)

1. F1. This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported.

Key Figures

Shares purchased: 2,600 shares Purchase price: $9.6294 per share Total direct holdings: 77,900 shares +1 more

4 metrics

Shares purchased 2,600 shares Common stock bought on 2026-08-11 by Chief Business Officer

Purchase price $9.6294 per share Average price for 2,600 common shares acquired

Total direct holdings 77,900 shares Direct holdings following the reported transaction

Unvested RSUs included 58,300 RSUs Unvested RSUs included in total holdings, subject to vesting schedule

Key Terms

Restricted Stock Units (RSUs), unvested RSUs, Chief Business Officer, Common Stock, par value $0.0001 per share

4 terms

Restricted Stock Units (RSUs) financial

"This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

unvested RSUs financial

"includes 58,300 unvested RSUs subject to the grant's vesting schedule"

Chief Business Officer financial

"Saxena Nishant C is reported as the company's Chief Business Officer"

A chief business officer (CBO) is the executive responsible for a company's commercial strategy, partnerships, licensing, and business development—essentially the leader who turns technology or products into paying customers and deals. Investors care because the CBO's choices about partnerships, pricing, market entry and revenue models directly influence how fast a company grows and how much future cash flow or value it can deliver; think of the CBO as the company's head coach for winning business and income.

Common Stock, par value $0.0001 per share financial

"security_title is Common Stock, par value $0.0001 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Corbus Pharmaceuticals (CRBP) report for Nishant C Saxena?

Corbus Pharmaceuticals reported that Chief Business Officer Nishant C Saxena purchased 2,600 shares of common stock on 2026-08-11 in a direct open-market or private transaction at an average price of $9.6294 per share.

At what price did the CRBP Chief Business Officer buy shares in this Form 4?

The Chief Business Officer of CRBP, Nishant C Saxena, bought 2,600 shares of common stock at an average price of $9.6294 per share on 2026-08-11, according to the Form 4 filing.

How many Corbus Pharmaceuticals (CRBP) shares does Nishant C Saxena hold after this transaction?

After the reported purchase, Nishant C Saxena directly holds 77,900 shares of Corbus Pharmaceuticals common stock. A filing footnote clarifies this total includes 58,300 unvested RSUs that remain subject to the grant’s vesting schedule.

Does the CRBP insider transaction involve unvested RSUs?

Yes. The Form 4 notes that 58,300 unvested RSUs are included in Nishant C Saxena’s total of 77,900 shares following the transaction, and these restricted stock units remain subject to the grant’s existing vesting schedule.

Was the CRBP insider share purchase under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not selected, meaning Nishant C Saxena’s 2,600-share purchase of CRBP common stock on 2026-08-11 was not reported as being made under a Rule 10b5-1 trading plan.

What role does Nishant C Saxena hold at Corbus Pharmaceuticals (CRBP)?

In the Form 4, Nishant C Saxena is identified as the company’s Chief Business Officer. He reported a direct open-market or private purchase of 2,600 shares of Corbus Pharmaceuticals common stock on 2026-08-11.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 04:30 PM Accepted by SEC EDGAR 08/12/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxena Nishant C

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/11/2026		P		2,600	A	$9.6294	77,900(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported.

	/s/Meghan Houghton, Attorney-in-Fact for Nishant Saxena	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)